Evicenter
MarkdownMedical informationP&T meetings
Palazestrant (OP-1250)

Previously treated ER-positive HER2-negative advanced or metastatic breast cancer

Manufacturer
Olema Oncology
Last updated
256 sources

Product information and disease descriptionPlace of product in therapyDisease description

Definition and etiology

11 evidence topics · 7 sources

Previously treated disease: endocrine resistance definitions

“Primary endocrine resistance is defined as relapse while on the first two years of adjuvant endocrine therapy for early breast cancer, or progressive disease within the first six months of first line endocrine therapy-based treatment for advanced breast cancer.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Secondary or acquired endocrine resistance encompasses all remaining clinical situations of endocrine resistance.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The first subgroup, early acquired endocrine resistance , includes relapse while receiving endocrine therapy but after the first two years, relapse within one year of completing adjuvant endocrine therapy, or progressive disease occurring after at least six months, but less than twelve months, of first line endocrine therapy-based treatment for advanced breast cancer.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The second subgroup, late acquired endocrine resistance , is defined as relapse more than twelve months after completing adjuvant endocrine therapy, or progressive disease after at least twelve months of first line endocrine therapy-based treatment for advanced breast cancer.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote